Becker's Healthcare June 25, 2024
By January 2025, Type 2 diabetes therapy Ozempic might be FDA approved for kidney disease-related events.
Novo Nordisk, the manufacturer of the popular medication, said June 24 the FDA has agreed to review a label extension based on positive phase 3 trial results. The study tested if Ozempic could reduce major kidney disease events among patients with diabetes and chronic kidney disease.
In late May, the Denmark-based drugmaker published the study findings: Ozempic cut the risk of kidney disease-related events by 24%, the risk of a major...
Today's Sponsors
Today's Sponsor